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S U M M A R Y
Meningococcal disease is a serious public health threat, especially during mass gatherings such as Hajj
and Umrah which provide optimal conditions for disease transmission. The disease is caused by Neisseria
meningitidis and transmitted mainly via asymptomatic carriers. A review of the literature on
asymptomatic N. meningitidis carriage among Hajj and Umrah pilgrims and their household contacts
was performed. Carriage studies reported carriage rates to be higher in Hajj pilgrims compared to Umrah
pilgrims and that these events promote acquisition of carriage among pilgrims. With some outliers, most
studies found carriage rates among pilgrims to be comparable to those in populations under non-
epidemic settings. However, these results should be interpreted with caution, taking into account the
limitations within the studies identiﬁed. A wide variety of N. meningitidis serogroups appear to be
circulating among Hajj and Umrah pilgrims, with serogroups W135 and B being most prominent. Current
Hajj and Umrah meningococcal disease preventative measures do not necessarily prevent carriage and
transmission, which may result in local and international outbreaks among susceptible populations.
Monitoring carriage states of visitors and local inhabitants in the Kingdom of Saudi Arabia, as well as the
implementation of preventive measures that impact carriage, are warranted to reduce the risk of Hajj
and Umrah-related meningococcal disease outbreaks.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Neisseria meningitidis is one of the leading causes of bacterial
meningitis globally and can also cause sepsis, pneumonia, and
other localized infections.1 Invasive meningococcal disease
remains a serious public health problem affecting up to 1.2 million
people annually and leading to between 50 000 and 135 000 deaths
worldwide.2 Even with appropriate treatment, the case fatality rate
is high, and the risk of long-term disabling sequelae of
meningococcal infection adds to the disease burden, especially
in developing countries.1 In total, 13 serogroups of N. meningitidis
have been reported, but only six (A, B, C, W135, X, and Y) cause
almost all life-threatening disease worldwide.3,4
The Kingdom of Saudi Arabia (KSA) hosts over two million
Muslim pilgrims annually from all over the world during the Hajj
period and several million pilgrims throughout the year for the* Corresponding author. Tel.: +96611401555 ext 1863.
E-mail address: saber.yezli@gmail.com (S. Yezli).
http://dx.doi.org/10.1016/j.ijid.2015.11.014
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Umrah religious mass gatherings in the holy cities of Mecca and
Medina. The Hajj pilgrimage is held on every 12th month of the
Islamic calendar, while the Umrah pilgrimage may be undertaken
at any time of the year. These mass gathering events create
conditions of overcrowding that are conducive to human-to-
human disease transmission, such as meningococcal disease.5 Hajj
and Umrah have been associated with a number of local and
international meningococcal disease outbreaks, including a large
serogroup A outbreak in 1987 and major serogroup W135
outbreaks in 2000 and 2001.6–9 Returning international pilgrims
carrying N. meningitidis were the vehicle for the exportation of the
disease outside KSA and also the introduction of new serogroups
into other regions of the world, affecting the global epidemiology
of the disease.3,10,11
A review of the literature on N. meningitidis carriage among Hajj
and Umrah pilgrims and their household contacts was performed.
The rate of carriage of the organism at these mass gatherings and
the serogroups circulating among pilgrims and their contacts is
reported here. A PubMed search of the relevant literature (up to
2015) was performed with a combination of the following terms:ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
S. Yezli et al. / International Journal of Infectious Diseases 47 (2016) 65–7066‘Neisseria meningitidis’, ‘meningococcal’, ‘carriage’, ‘Hajj’, ‘Umrah’,
‘pilgrims’, and ‘pilgrimage’. Reference lists of relevant articles were
also hand-searched to identify further material.
2. Asymptomatic carriage of N. meningitidis
Asymptomatic carriage of N. meningitidis was ﬁrst described in
Europe in 189612 and occurs in 8–25% of the human population,
with adolescents being the major reservoir.2 Meningococci are
spread from person to person through direct contact with
oropharyngeal secretions, and asymptomatic carriers are the
primary source of N. meningitidis transmission under both
epidemic and endemic conditions.1,13 Although asymptomatic
carriage of both pathogenic and non-pathogenic strains is
common, few carriers develop invasive disease. For the majority
of people, carriage is an immunizing process that results in a
systemic, serogroup-speciﬁc protective antibody response.1 Vac-
cination with the polysaccharide vaccines does not prevent the
acquisition of carriage, but there is evidence that conjugate
vaccines do impact the carriage state.1,13–15 For instance, the use of
monovalent meningococcal conjugate vaccines in routine univer-
sal vaccination programs were associated with reductions in
carriage and a consequent herd effect, such as reductions of
invasive meningococcal disease in unvaccinated age cohorts.15
The prevalence of meningococcal carriage differs within and
between countries, varying across age groups, serogroup distribu-
tion, and over time. The rate is also inﬂuenced by contact with
cases and the epidemic/endemic situation. For example, the
reported prevalence of meningococcal carriage in the USA is
5–10% under non-epidemic conditions.16 In comparison, a carriage
prevalence of between 3% and 30% has been documented for the
African meningitis belt.17 In closed populations, such as among
military recruits, carriage can reach levels of 40–80%.18
3. Carriage of N. meningitidis at the Hajj and Umrah mass
gatherings
There are several risk factors associated with meningococcal
carriage. These include crowded conditions (e.g., military barracks,
dormitories, events), travel to endemic areas, personal behaviors
(e.g. kissing, coughing, smoking), and respiratory viruses and
Mycoplasma.6,13,19 In this context, mass gatherings such as the Hajj
and Umrah are very relevant. These events are characterized by
heavily overcrowded conditions of a pilgrim population originat-
ing from diverse geographical areas. These pilgrims all live for
extended periods of time in close proximity to each other, with
shared facilities, and perform exhausting religious rites. These are
optimal conditions for meningococcal exposure and colonization
of susceptible individuals and carrier-to-carrier acquisition of
strains, as well as increased rate of new carrier acquisition.6 It is
not surprising that a very high prevalence of asymptomatic
N. meningitidis carriage has been reported at such events, with a
rate of up to 86% documented for Mecca pilgrims in 1992.7
Local data show that the carriage rate of N. meningitidis among
the population is higher in cities hosting the Hajj and Umrah mass
gatherings compared to other regions of KSA. Two such studies,
one performed by Ashoor and Turkestani20 and the other by
Kholeidi et al.,21 both outside the Hajj pilgrimage season, showed
the carriage rate among locals from Mecca to be higher than that in
those from Medina (the second most holy city for Muslims) and
also higher than that among local inhabitants from the city of
Riyadh, where there is no contact with pilgrims; rates were 1.1%,
0.1%, and 0%, respectively. Another study conducted during the
2001 pilgrimage found the carriage rate among the local
population of Jeddah and Mecca to be 4.7%.22 Serogroup W135
accounted for 40% of the meningococci isolated, while only 6.5%were serogroup A and 13% were serogroup B. This is not surprising
given that serogroup W135 was the outbreak strain in the
2000 and 2001 Hajj seasons.6,23
3.1. Rate of N. meningitidis carriage among Hajj pilgrims
A number of N. meningitidis carriage studies have been
conducted on Hajj pilgrims (Table 1). Most of these studies have
reported an overall carriage rate of 5–10%, which is comparable to
those found in populations in non-epidemic settings.16 However,
there are some outliers. For example, studies among pilgrims from
the USA in 200124 and Singapore in 200225 found signiﬁcantly
lower carriage rates of only 1.9% and 1.7%, respectively. More
recently, Benkouiten and colleagues did not detect N. meningitidis
carriage among 298 French pilgrims sampled before and after the
2013 Hajj,26 while Ceyhan et al. reported a high (18.7%) overall
carriage rate among Turkish pilgrims attending the 2010 Hajj.27
Several studies have also documented the effect of Hajj on the
acquisition of carriage (Table 1), the majority of which found that
the pilgrimage increased N. meningitidis carriage. However a
number of studies have found carriage rates among pilgrims post-
Hajj to be lower than those pre-Hajj, even among the same cohorts
of pilgrims.25,28,29
The above ﬁndings however need to be put into context
considering a number of important factors. First, most of these
carriage studies were conducted in small cohorts of country-
speciﬁc pilgrim populations.
Second, given the demographics of Hajj pilgrims, carriage studies
during the event were conducted on a mostly adult population. The
N. meningitidis carriage rate differs with age, with a rate of <3% in
children younger than 4 years, increasing to 24–37% in the age group
15–24 years, and decreasing to <10% in older age groups.13
Third, most of these carriage studies were conducted during, or
soon after, the 2000 and 2001 international Hajj-related menin-
gococcal disease outbreaks. Hence, they were performed at a time
when a number of meningococcal disease prevention measures
had been introduced, both in Saudi Arabia and internationally, to
prevent future outbreaks. Of note is the introduction of compulso-
ry meningococcal vaccination with the quadrivalent (A/C/W/Y)
vaccine by 2002 for all pilgrims before attending Hajj.6 The Saudi
recommendations do not yet specify which vaccine technology
should be used. Although licensed since 2005, the quadrivalent
conjugate meningococcal vaccine is still not used universally by all
countries participating in Hajj.30 In most of the Hajj carriage
studies the majority of pilgrims, if not all of them, received
meningococcal vaccination (Table 1). Vaccination using the
polysaccharide quadrivalent vaccine does not prevent carriage,
nor does it eradicate existing meningococcal carriage.1,27 The effect
of the polysaccharide vaccines on colonization and the transmis-
sion of the organisms are transient or negligible.13 However,
vaccination protects pilgrims from invasive disease and has been
linked to a signiﬁcant reduction in cases of disease during Hajj.8
The effect of vaccinating the entire Hajj population led to a
reduction in invasive disease, which would have impacted carriage
rates.31,32
Fourth, antibiotic use among pilgrims was found to vary
between studies, ranging from 13% to 59% (Table 1). This factor is
partially relevant for studies reporting carriage rates in pilgrims
post-Hajj. Antibiotic use is common during Hajj and can lead to a
reduction or elimination of N. meningitidis carriage. In one study,
a single dose of ciproﬂoxacin (500 mg) given to a cohort of
Iranian pilgrims 24 h before leaving Hajj reduced the carriage
rate from 8.1% before Hajj to 0% post-Hajj.29 In another study,
N. meningitidis carriage was not detected post-Hajj among
177 Kuwaiti pilgrims, 83% of whom received one dose of
ciproﬂoxacin before leaving Hajj.33
Table 1
Rate of Neisseria meningitidis carriage among Hajj pilgrims and their household contacts
Study
population
Study
year
Overall
carriage (%)
Carriage
pre-Hajj (%)
Carriage
post-Hajj (%)
Notes Ref.
Pilgrims Pilgrims Pilgrims Household
contacts
USAa 1987 - - 37/318 (11.6) - 17% of 192 travelers received
meningococcal vaccination.
15% of 186 travelers used rifampicin
during their stay in Saudi Arabia.
18
Singapore 2001 30/375 (8) 1/204 (0.5) 29/171b (17) 19/233 (8.2) Rate of antibiotic use in returning
pilgrims was 41%.
35
8 countries 2001 134/1458 (9.2) 57/715 (8) 77/743 (10.4) - Some pilgrims had received
meningococcal vaccination.
49
USA 2001 22/1153 (1.9) 4/452 (0.9) 18/701 (2.6) - Carriage rate among returning non-
pilgrims was 2.7% (3/112).
Rate of antibiotic use was 15% and
44.8% in the pre-Hajj and post-Hajj
groups, respectively.
Over 97% of pilgrims were vaccinated
with the quadrivalent polysaccharide
vaccine.
24
Thailand 2001 - - 0/374 (0) - 77.8% of pilgrims were vaccinated
against meningococcal infection.
50
Singapore 2001 - - 61/373 (16.4) 13/117 (11.1) 55% of carriers remained positive
after 5–6 months.
All pilgrims were vaccinated with the
quadrivalent polysaccharide vaccine.
Some pilgrims took antibiotics during
Hajj.
31
Singapore 2002 6/346 (1.7) 4/193 (2.6) 2/153b (1.3) - All pilgrims were vaccinated with the
quadrivalent polysaccharide
meningococcal vaccine.
Rate of antibiotic use in returning
pilgrims was 53%.
25
UK 2002 32/427 (7.5) 21/253 (8.3) 11/174 (6.3) 9/70c (12.9) All pilgrims were vaccinated with the
quadrivalent polysaccharide vaccine.
Rate of antibiotic use in returning
pilgrims was 21%.
28
29 countries 2003 11/344 (3.2) At least 44% of pilgrims were
vaccinated against meningitis in the
previous 4 years (92% with the
quadrivalent vaccine and 8% with the
bivalent vaccine).
12.8% of 163 pilgrims took antibiotics
during Hajj.
42
Iran 2003 66/1348 (4.9) 35/674 (5.2) 31/674b (4.6) - 3 new serogroups identiﬁed in
returning pilgrims (Z, Z0 , and A).
All pilgrims received the quadrivalent
polysaccharide vaccine.
At least 58.2% of post-Hajj pilgrims
took antibiotics during Hajj.
29
Iran 2003 - 10/123 (8.1) 0/123b (0) - All pilgrims were given one dose of
500 mg ciproﬂoxacin 24 h before
leaving Hajj.
All pilgrims received the quadrivalent
polysaccharide vaccine.
29
Kuwait 2005 - - 0/177b (0) - 92% of the pilgrims were vaccinated
with the meningococcal quadrivalent
vaccine.
83% of pilgrims received one dose of
ciproﬂoxacin before leaving Hajj.
33
14 countries 2009 152/2046 (7.3) 84/1433 (6) 68/613d (11) - - 36
Turkey 2010 144/768 (18.7) 63/472 (13) 81/296b (27) 10/39c (25.6) All pilgrims were vaccinated using the
quadrivalent polysaccharide vaccine.
27
Iran 2012 6/844 (0.7) 0/422 (0) 6/422b (1.4) - 58.5% of pilgrims took antibiotics
during Hajj.
All pilgrims received the quadrivalent
polysaccharide vaccine.
51
France 2012–13 0/596 (0) 0/298 (0) 0/298b (0) - - 26
a High-risk travelers (including pilgrims and non-pilgrims) who visited Mecca and Medina during the Hajj season.
b The same pilgrims sampled pre-Hajj.
c Contacts of carrier pilgrims.
d The same pilgrims or pilgrims from the same Hajj group.
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rates, including poor sampling techniques, differences in labora-
tory methods, and the rapid autolytic rate of meningococcus, as
well as differences in living conditions, degree of overcrowding, or
social activities during the Hajj in the populations studied.22,31
3.2. Rate of N. meningitidis carriage among Umrah pilgrims
Few studies have reported meningococcal carriage during
Umrah. Wilder-Smith and colleagues investigated 160 Singaporean
pilgrims returning from Umrah pilgrimage in 2001.34 The carriage
rate was 1.3%, which was signiﬁcantly lower than that found in
returning Singaporean Hajj pilgrims (17%; p < 0.001) in the same
year.35 None of the Umrah pilgrims carried serogroup W135,
whereas 90% of the isolates from retuning Hajj pilgrims were
serogroup W135.34,35 A similar statistically signiﬁcant difference
in results was noted by Ashgar et al., who reported an overall
carriage rate of N. meningitidis of 4% among Umrah visitors and
pilgrims compared to 7.3% (p < 0.0001) among Hajj pilgrims in
2009.36 The carriage rate increased from 2.4% before Umrah to 5.7%
after Umrah. These differences may be explained by the fact that
the length and intensity of interaction among the pilgrims during
the Hajj is far greater than during the Umrah.
3.3. N. meningitidis serogroups carried by pilgrims
Carriage studies conducted on Hajj and Umrah pilgrims have
shown a wide variety of N. meningitidis serogroups to be circulating
during these mass gatherings (Table 2). Serogroups W135 and B
appear to be dominant, which mirrors the epidemiology of
serogroups causing disease in Saudi Arabia and in countries of the
populations investigated.8,37 Other serogroups were also identiﬁed,
including serogroups A, C, D, E, Y, X, Z, and Z0. Hence, the six
serogroups causing almost all life-threatening disease worldwide (A,
B, C, W135, and Y)37were all found to be circulating among pilgrims.
In reviewing the literature on N. meningitidis carriage among
pilgrims it is clear that serogroup W135 has become the
predominant serogroup since the 2000 outbreak. Carriage of
W135 was ﬁrst reported in one US traveler returning from Saudi
Arabia during the 1987 Hajj season.18 High levels of asymptomatic
carriage of W135 meningococcus strains belonging to the ET-37
clonal complex (involved in Hajj outbreaks) were found during aTable 2
Prevalence of various serogroups among Neisseria meningitidis isolates from pilgrim ca
Study
population
Study
year
Prevalence of serogroup in pre-Hajj
isolates (%)
Prevalen
n Pilgrims n 
USAa 1987 - 37 
Singapore 2001 1 X (100) 29 
8 countries 2001 57 W135 (5.3),
A (5.3), B (15.8), X (14),
Y (7), NS (50.8)
77 
USA 2001 4 B (50), Y (50) 18 
Singapore 2001 - 61 
Singapore 2002 4 B (25), NS (75) 2 
UK 2002 21 W135 (9.5), B (23.8),
NS (66.6)
11 
Iran 2003 35 W135 (2.8), B (25.7),
C (14.2), D (14.2),
Y (14.2), NS (28.5)
31 
Turkey 2010 63 W135 (82.5), A (14.3),
B (1.6), Y (1.6)
81 
n, total number of isolates; NS, non-serogroupable.
a High-risk travelers (including pilgrims and non-pilgrims) who visited Mecca and Mvaccine trial in children in Gambia in 1996.38 This serogroup has
been recovered regularly from pilgrims since the 2000 outbreak
(Table 2), sometimes with an overwhelming prevalence among
N. meningitidis isolates. With few exceptions,28,29 serogroup W135
has accounted for 44–100% of isolates from returning pilgrims and
42–100% of their household contacts. In a recent study, W135
accounted for 82.5% of isolates from Turkish pilgrims sampled pre-
Hajj, 91.3% of those from pilgrims sampled post-Hajj, and all
isolates recovered from household contacts of carrier pilgrims.27
Serogroup B N. meningitidis has also been isolated regularly
from pilgrims both pre- and post-Hajj, at a rate of 9–25% among
isolates (Table 2). In one study, the prevalence of serogroup B
among isolates from UK pilgrims was 24% pre-Hajj and 27% post-
Hajj, and comprised 22% of isolates recovered from household
contacts of returning carrier pilgrims.28 In general, serogroup B
appears to have been the dominant isolated serogroup among pre-
Hajj pilgrims, probably reﬂecting the epidemiology of meningo-
coccal disease in the countries from where the studied pilgrims
originated.37 The regular isolation of serogroup B N. meningitidis
from pilgrims is concerning. The current compulsory meningococ-
cal vaccination for Hajj and Umrah pilgrims with the quadrivalent
ACYW135 vaccine does not protect against disease caused by
serogroup B. In addition, many counties with large Muslim
populations have been experiencing trends of increased serogroup
B meningococcal disease.39 There is thus the threat of a sudden
change in the etiology of meningococcal disease during these mass
gatherings.
3.4. Carriage of non-serogroupable N. meningitidis among pilgrims
A stable feature of carriage studies performed during Hajj and
Umrah is the high proportion of non-serogroupable N. meningitidis
among pilgrims and household contacts. Capsular polysaccharides
are the outermost antigens on the meningococcal surface and the
prime target for mucosal and humoral immunity.4,13 Patient
strains are encapsulated. In contrast, approximately 50% of the
strains isolated from carriers lack the capsule and are therefore
serologically not groupable.13 The carriage rate of such isolates in
pilgrims was found to range between 28% and 75% (Table 2). The
signiﬁcance of these isolates is not clear. Non-serogroupable
meningococci were formerly assumed to be non-pathogenic, but it
was found that capsule production in meningococcal strains canrriers and their household contacts
ce of serogroup in post-Hajj isolates (%) Ref.
Pilgrims n Household contacts
A (91.9) - 18
W135 (89.6) 19 W135 (42.1) 35
W135 (44.2),
B (3.9), X (3.9),
NS (46.7)
- 49
W135 (50), B (16.6),
NS (27.7)
- 24
W135 (91.8) 13 W135 (69.2) 31
W135 (100) - 25
W135 (9.1), B (27.3),
E (9.1),
NS (54.5)
9 W135 (22.2),
B (22.2), NS (55.6)
28
W135 (3.2), A (3.2),B (6.4),
C (3.2), Y (6.4), Z (3.2),
Z0 (6.4), NS (67.7)
- 29
W135 (91.3), A (6.2),
B (1.2), Y (1.2)
10 W135 (100) 27
edina during the Hajj season.
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the expression of virulence factors that include the capsule is
common.13,40 The loss of the capsule may enhance the capability of
meningococci to colonize the human nasopharynx and avoid the
human defense systems.13 There is accumulating evidence of the
pathogenic potential of strains that are not groupable by standard
slide agglutination (SASG).41
Many carriage studies performed on pilgrims and their contacts
have used SASG methods to serogroup isolates.22,25,31,42 Hence data
from such studies should be interpreted with caution as they may
have underreported the carriage of potentially pathogenic strains.
An example of this comes from the work by Dull et al., who evaluated
the carriage of N. meningitidis among US travelers to the 2001 Hajj.24
Of the 25 N. meningitidis isolates obtained, 15 (60%) were non-
serogroupable when tested by SASG techniques. However, using
PCR, nine (60%) of the non-serogroupable isolates were character-
ized as serogroups W135 (n = 2), B (n = 4), and Y (n = 3). In one
instance, an N. meningitidis serogroup W135 isolate was recovered
from an elderly male pilgrim. His wife was also a carrier, but her
isolate was not groupable by SASG. When the two strains were
further evaluated by molecular and phenotypic techniques, they
were found to be identical except for capsule expression.24
3.5. Carriage of N. meningitidis among household contacts of
returning pilgrims
Carriage studies have also indicated that household contacts of
returning pilgrims are colonized by meningococci carried by
pilgrims. Although vaccination may protect the pilgrims from
invasive disease, carriage data show that returning pilgrims
represent a sizeable reservoir of transmissible and sometimes
persistent meningococcal clones, which places their unvaccinated
family contacts (and possibly the community at large) at risk of
invasive disease. This is all the more relevant given that carriage of
N. meningitidis can persist for prolonged periods of time both
among returning pilgrims and their household contacts.31,43
Wilder-Smith et al.31 reported that 55% of carrier pilgrims and
50% of their contacts carriers remained positive for up to 6 months.
This long duration of carriage indicates that returning pilgrims
may represent an ongoing threat to the community. For instance
cases of W135 disease were identiﬁed in the UK several months
after the end of the Hajj, but most of these case-patients had had no
identiﬁable direct contact with Hajj pilgrims.44
Household contacts of returning pilgrims have been implicated
in international Hajj-related meningococcal disease outbreaks.45–
47 The estimated attack rate of the W135 disease for household
contacts of returning Singaporean pilgrims was 18 cases per
100 000 contacts for the outbreak year of 2000 and 28 cases per
100 000 contacts for the outbreak year of 2001.11 On the basis of
rates of transmission of W135 carriage and epidemiological data,
the calculated risk that an unvaccinated household contact who
has acquired W135 carriage will develop invasive meningococcal
disease was estimated to be 1 case per 70 acquisitions.11
The reported rate of meningococcal carriage among household
contacts of returning pilgrims was found to vary between studies,
ranging from 8% to 25% (Table 1). Household contacts are generally
colonized by the same clones carried by the returning pilgrims.
Ceyhan et al. reported that 25.6% of household contacts of pilgrims
(all carrying the meningococcal serogroup W135) were also
carriers of the same serogroup, and that the clonal structure of
the bacteria was the same as the source cases.27 The rate of
transmission to household contacts in the study was similar to that
observed among household contacts of patients with meningo-
coccal disease (20.5%).48 Wilder-Smith et al.35 reported a lower
rate of transmission of 8.2% among household contacts of returning
pilgrims. This may be explained by the fact that only 29% of theretuning pilgrims were carriers. Nevertheless, 42% of the contacts
carried the W135 clone, which was prevalent in 90% of the isolates
from returning pilgrims. All but one of the contacts carrying the
W135 clone were contacts of returning pilgrims colonized with
W135. These results are in line with rates of acquisition of the same
strain by contacts of patients with meningococcal diseases (50%).48
4. Concluding remarks
Due to the potential for contact and epidemic spread, rapid
onset, high case-fatality rate, and neurological sequelae of
meningococcal disease, a single case is of immediate public health
importance, especially during mass gathering events such as Hajj
and Umrah. These events create optimal conditions for disease
transmission, including that of meningococcal disease. Several Hajj-
related meningococcal disease outbreaks have been documented,
including international outbreaks of serogroups A and W135. These
outbreaks were exported outside KSA via returning pilgrims
carrying the organism who transmitted this to their contacts.
We reviewed the literature on N. meningitidis carriage among
Hajj and Umrah pilgrims and their household contacts. Carriage
studies have reported the rate of N. meningitidis colonization
among the population to be higher in cities hosting the Hajj and
Umrah mass gatherings compared to other regions of KSA. Also,
carriage rates have been higher in Hajj pilgrims compared to
Umrah pilgrims and both of these events promote the acquisition
of the carriage state. With some outliers, most studies have found
carriage rates among pilgrims to be comparable to those in
populations in non-epidemic settings. A considerable variation in
reported carriage rates was found, which may be a reﬂection of the
impact of a number of factors including the year of pilgrimage, the
population investigated, antibiotic use, and vaccination status, as
well as the sampling and laboratory techniques used.
A wide verity of N. meningitidis serogroups appear to be
circulating among Hajj and Umrah pilgrims, with serogroups
W135 and B being dominant. This is of concern, given that the
current meningococcal disease preventive measures for Hajj and
Umrah do not protect against serogroup B. The current preventive
measures of KSA include compulsory vaccination with the
quadrivalent vaccine (ACYW135) issued no more than 3 years
and no less than 10 days before arrival in Saudi Arabia. For visitors
arriving from countries in the African meningitis belt, chemopro-
phylaxis is also administered at the port of entry to lower the rate
of carriers. Available preventive measures against meningococcal
disease caused by serogroup B should be considered in preparation
for a sudden change in the etiology of meningococcal disease
during the Hajj and Umrah.
The current Hajj and Umrah health requirements have been
effective in reducing meningococcal cases during these mass
gatherings and in preventing outbreaks related to these events in
the last few years. However, as vaccination does not prevent
carriage and transmission of the organism, returning pilgrims
carrying N. meningitidis after Hajj or Umrah represent a sizeable
reservoir of transmissible and persistent clones, which places their
unvaccinated family contacts, and potentially the community at
large, at risk of invasive disease. This issue needs to be addressed
by an appropriate public health intervention which may include
prophylaxis at the point of departure, vaccination of the pilgrims’
contacts, and reinforcement of the current preventive measures. A
move towards the use of conjugate quadrivalent vaccine for
pilgrims will be most beneﬁcial because of the potential for
reducing transmission by preventing/clearing carriage. Such public
health interventions need to be evidence-based and take into
consideration the potential for the development of antibiotic
resistance, rate of uptake of the vaccine by pilgrims and their
contacts, and the cost and effectiveness of the preventive measure.
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coccal disease is ultimately more informative to guide interven-
tions for disease prevention than investigating carriage of the
organism. However, continued surveillance of the characteristics
of the N. meningitidis carrier state in the population in Saudi Arabia
and among Hajj and Umrah pilgrims will assist in understanding
the changing epidemiology and pathogenesis of the organism and
in predicting and possibly preventing epidemic outbreaks during
future Hajj and Umrah pilgrimages. Such outbreaks could be
caused by the emergence of new serogroups in KSA, such as
serogroup B or X, or new meningococcal clones resulting from
genetic exchange with other bacteria during the carriage state.
Carriage investigations including during outbreaks should include
the molecular characterization of isolates to avoid underestima-
tion of true carriage and genotype-speciﬁc attack rates. Finally,
investigation of the carrier state may contribute signiﬁcantly to our
understanding of the main mechanisms involved in the establish-
ment of a commensal relationship between the bacterium and the
host, and the link between meningococcal carriage and disease,
which has been a fundamental question in meningococcal biology
and pathogenesis.
Ethical approval: Not required
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